Medicinal products - Latest updates

Civil Society representatives: Call for expressions of interest for the EMA PDCO Committee

New and updated documents - EudraLex Volume 10: Clinical trials guidelines

Statement by Commissioner Várhelyi ahead of the 30th anniversary of EU medicines approval

Commission publishes new measures for the better lifecycle management of medicine authorisations

Commission authorises medicine to treat postpartum depression

Stakeholders’ Consultation on EudraLex Volume 4 - Good Manufacturing Practice Guidelines: Chapter 1

Document summarising evidence supporting the legislative proposal for strengthening the availability, supply and production of critical medicines within the EU

Commission staff working document on the use of titanium dioxide in medicinal products

Stakeholders’ Consultation on EudraLex Volume 4 - Good Manufacturing Practice Guidelines: Chapter 4, Annex 11 and New Annex 22

Webinar for Sponsors – COMBINE pilot 'all-in-one' procedure

Commission grants conditional authorisation medicine for treatment of Duchenne muscular dystrophy

Commission adopts temporary restriction on use of Chikungunya vaccine for older patients

Summary record - 102nd meeting of the Pharmaceutical Committee (1 April 2025)

Presentation materials - Info session on the Commission’s proposal for a Critical Medicines Act (29 April 2025)

Registration - Info session on the Commission’s proposal for a Critical Medicines Act (29 April 2025, 15:30 - 17:00 (CEST))

Commission authorises medicine for treatment of early Alzheimer’s disease

Updated list of nominated representatives from their respective Member State (28 March 2025)

Update - MedEthicsEU report - Survey on National Part II Clinical Trial Application (CTA) requirements (March 2025)

Agenda - 102nd meeting of the Pharmaceutical Committee (1 April 2025)